Citation Impact

Citing Papers

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
Inflammation and Alzheimer's disease
2000 Standout
5 Selective Inhibitors of Cyclooxygenase-2 (COT-2)
1999
Bruxism physiology and pathology: an overview for clinicians*
2008 Standout
Future trends in the development of safer nonsteroidal anti-inflammatory drugs
1998
Meta-Analysis of Quantitative Sleep Parameters From Childhood to Old Age in Healthy Individuals: Developing Normative Sleep Values Across the Human Lifespan
2004 Standout
Anti-inflammatory Plant Flavonoids and Cellular Action Mechanisms
2004 Standout
Enantioselective rhodium-catalyzed addition of arylboronic acids to trifluoromethyl ketones
2006 StandoutNobel
Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials
1999
COX-2 Selective Nonsteroidal Anti-Inflammatory Drugs
2000
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
2000 Standout
COX-2???Specific Inhibitors: Definition of a New Therapeutic Concept
2001
Meloxicam: Selective COX-2 inhibition in clinical practice
1997
Meloxicam
1996
Cyclo-Oxygenase Isoenzymes
1997
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
1999 Standout
Gastrointestinal tolerability of meloxicam and piroxicam: a double‐blind placebo‐controlled study
1998
Cyclic alternating pattern (CAP) in normal sleep: polysomnographic parameters in different age groups
1998
COX-2 inhibitors
1999 Standout
Synthesis of Heterocycles via Electrophilic Cyclization of Alkynes Containing Heteroatom
2011 Standout
Origin and Significance of the Cyclic Alternating Pattern (CAP)
2000
CYCLOOXYGENASES 1 AND 2
1998 StandoutNobel

Works of Scott Dellorso being referenced

Changes of cyclic alternating pattern (CAP) parameters in situational insomnia under brotizolam and triazolam
1995
A 4-Week, Double-Blind, Parallel-Group Study to Compare the Gastrointestinal Effects of Meloxicam 7.5 mg, Meloxicam 15 mg, Piroxicam 20 mg and Placebo by Means of Faecal Blood Loss, Endoscopy and Symptom Evaluation in Healthy Volunteers
1996
Rankless by CCL
2026